TY  - CHAP
M1  - Book, Section
TI  - Male Sexual Dysfunction
A1  - Reed-Maldonado, Amanda B.
A1  - Lue, Tom F.
A2  - McAninch, Jack W.
A2  - Lue, Tom F.
PY  - 2020
T2  - Smith & Tanagho's General Urology, 19e
AB  - It  is  estimated  that  more  than  half  of  men  aged  40–70  in  the  United  States  are  unable  to  attain  or  maintain  a  penile  erection  sufficient  for  satisfactory  sexual  performance.  Advances  in  pharmacologic  therapy  for  erectile  dysfunction  (ED),  coupled  with  a  better  understanding  of  male  sexual  dysfunction,  have  resulted  in  greater  numbers  of  patients  seeking  care  for  sexual  concerns.  Oral  phosphodiesterase  type  5  inhibitors  have  emerged  as  the  preferred  first-line  treatment  of  ED  worldwide  because  of  their  efficacy,  ease  of  use,  and  patient  safety.  Erectile  function  can  now  be  evaluated  by  the  response  to  these  agents  at  home  or  by  assessment  of  response  to  intracavernous  injection  (ICI)  of  vasoactive  agents  in  the  office,  and  improved  diagnostic  tests  can  differentiate  among  types  of  impotence.  Patient  satisfaction  with  penile  prostheses  is  high,  as  the  latest  generation  of  devices  is  more  sophisticated  and  durable  than  ever.  Current  treatments  continue  to  evolve  and  new  therapies,  such  as  low-intensity  extracorporeal  shockwave,  stem  cell,  and  gene  therapies,  may  represent  the  next  generation  of  more  physiologic  and  disease-specific  solutions  to  various  types  of  ED  (Melman  et  al,  2007;  Lin  et  al,  2017;  Bahk  et  al,  2010).  
SN  - 
PB  - McGraw Hill
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesssurgery.mhmedical.com/content.aspx?aid=1171186175
ER  -